Название продукции:5-bromo-1H-pyrazolo[3,4-b]pyridine

IUPAC Name:5-bromo-1H-pyrazolo[3,4-b]pyridine

CAS:875781-17-2
Молекулярная формула:C6H4BrN3
Чистота:95%+
Номер в каталоге:CM103832
Молекулярная масса:198.02

Упаковочная единица Доступно для заказа Цена ($) Количество
CM103832-100g in stock ŵưǶ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:875781-17-2
Молекулярная формула:C6H4BrN3
Точка плавления:-
Smiles-код:BrC1=CN=C(NN=C2)C2=C1
Плотность:
Номер в каталоге:CM103832
Молекулярная масса:198.02
Точка кипения:
Номер Mdl:MFCD05663982
Хранение:Store at room temperature

Category Infos

Pyrazolopyridines
Over the past few years, many pyrazole fused-ring systems, especially with applications in medicinal chemistry, have been published. These include general structures such as pyrazoline, pyrazoline, pyrazoquinoline, pyrazoloisoquinoline, pyrazoline, pyrazolopyrazine, pyrazolopyrazine, pyranopyrazole, pyrano Pyrazoles, pyrazolotriazines and pyrazole fused phosphorus rings.

Column Infos

Olverembatinib
Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs.